1.

Tata Capital Growth Fund plans to acquire how much percent of stake in Biocon Biologics India for 30 Million USD?

Answer» On 31st July 2020, Biocon Biologics India approved the primary equity investment of around Rs.225 crore (30 Million USD) by Tata Capital Growth Fund for a 0.85% minority stake in Biocon Biologics, biosimilar business, at an equity valuation of around Rs. 26,250 crore (3.5 billion USD) and enterprise valuation of around Rs. 30,400 crore (4 billion USD).


Discussion

No Comment Found